Evidence map›Paper›PMID 24381622›Full record

ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2013

Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model.

Arash Mirabzadeh, Enayatollah Bakhshi, Mohamad Reza Khodae, Mohamad Reza Kooshesh, Bibi Riahi Mahabadi, Hossein Mirabzadeh, Akbar Biglarian

Open access · greenAbstract read
In one paragraph

Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Arash MirabzadehDepartment of Psychiatric, Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran.
Enayatollah BakhshiDepartment of Biostatistics, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran.
Mohamad Reza KhodaeDepartment of Psychiatric, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran.
Mohamad Reza KoosheshMaster of Sciences of Psychology, Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran.
Bibi Riahi MahabadiMaster of Sciences of Psychology, Family Clinic, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran.
Hossein MirabzadehMaster of Industrial Psychology, Tehran, Iran.
Akbar BiglarianDepartment of Biostatistics, University of Social Welfare and Rehabilitation Sciences (USWRS), Tehran, Iran.
University of Social Welfare and Rehabilitation Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntipsychotic monotherapy or polypharmacy (concurrent use of two or more antipsychotics) are used for treating patients with psychiatric disorders (PDs). Usually, antipsychotic monotherapy has a lower cost than polypharmacy. This study aimed to predict the cost of antipsychotic medications (AM) of psychiatric patients in Iran. MATERIALS AND

methodsFor this purpose, 790 patients with PDs who were discharged between June and September 2010 were selected from Razi Psychiatric Hospital, Tehran, Iran. For cost prediction of AM of PD, neural network (NN) and multiple linear regression (MLR) models were used. Analysis of data was performed with R 2.15.1 software.

resultsMean ± standard deviation (SD) of the duration of hospitalization (days) in patients who were on monotherapy and polypharmacy was 31.19 ± 15.55 and 36.69 ± 15.93, respectively (P < 0.001). Mean and median costs of medication for monotherapy (n = 507) were $8.25 and $6.23 and for polypharmacy (n =192) were $13.30 and $9.48, respectively (P = 0.001). The important variables for cost prediction of AM were duration of hospitalization, type of treatment, and type of psychiatric ward in the MLR model, and duration of hospitalization, type of diagnosed disorder, type of treatment, age, Chlorpromazine dosage, and duration of disorder in the NN model.

conclusionOur findings showed that the artificial NN (ANN) model can be used as a flexible model for cost prediction of AM.

Indexed as

Linear regressionneural networkspsychiatric disorderstreatment cost

Identifiers

PMID24381622
PMCPMC3872587
OpenAlexW1731860819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.